Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans
Yale University
Summary
The goal of this fixed order, open-label, dose-escalation study is to investigate the safety and efficacy of specific doses of dimethyltryptamine (DMT) in humans.
Description
The results of this study will inform the doses to be used in a larger, double-blind, randomized, placebo-controlled, crossover study. Since the goal of the open label study is to inform the double-blind, randomized, placebo-controlled study, the investigators are citing the hypothesis of the latter solely for providing context. The investigators hypothesize that the administration of DMT will result in neuroplastic changes in healthy and depressed subjects. These changes in neuroplasticity will be indexed using electroencephalographic (EEG) measures and tasks. These neuronal changes may in pa…
Eligibility
- Age range
- 21–65 years
- Sex
- All
- Healthy volunteers
- Yes
Healthy controls inclusion criteria: * Medically healthy * Psychiatrically healthy Healthy controls exclusion criteria: * Unstable medical conditions * Psychiatric illness Depression inclusion criteria: * Medically healthy * Diagnosis of major depressive disorder Depression exclusion criteria: -Unstable medical conditions
Interventions
- Drug0.1 mg/kg Dimethyltryptamine (DMT)
0.1 mg/kg DMT
- Drug0.3 mg/kg Dimethyltryptamine (DMT)
0.3 mg/kg DMT
Location
- Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of MedicineWest Haven, Connecticut